The combined treatment of lapatinib with conventional chemotherapeutic agents such as cisplatin, topotecan, and doxorubicin showed synergistic effects on the inhibition of cancer cell growth by directly inhibiting BCRP-mediated drug efflux activity [42, 43]. Here, ABCG2 is linked to cancer.